The Lynx Group

NCCN Congress Highlights

New York, NY—The FDA approvals of obinutuzumab (Gazyva), ofatumumab (Arzerra), ibrutinib (Imbruvica), and idelalisib (Zydelig) have changed the treatment paradigm of patients with chronic lymphocytic leukemia (CLL).
Read Article

New York, NY—In a debate on the role of rituximab (Rituxan) maintenance therapy in patients with follicular lymphoma at the 2014 National Comprehensive Cancer Network Congress, the protagonist and antagonist were not that far apart.
Read Article

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to receive the free VBCC print publication or weekly e‑Newsletter.

I'd like to receive: